SHALI MED LTD
REGISTERED NUMBER: 14008891
STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Creditors: amounts falling due within one year
|
|
|
|
|
Net current (liabilities)/assets
|
|
|
|
|
Total assets less current liabilities
|
|
|
|
|
Creditors: amounts falling due after more than one year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes
The company is registered in England and its registered number is 14008891. The company is a private
company limited by shares. Its registered office is Oakleigh Pharmacy, Dellata House, Uxbridge Road, Uxbridge UB10 0LU.
Arrangements not reflected in the Statement of financial position
|
At 31 March 2024, the company had total commitments under non-cancellable operating leases over the
remaining life of those leases of £239,918 (2023: £NIL).
Average number of employees
|
The average monthly number of employees, including directors, during the year was 0 (2023 - 0).
The company had bank loans totalling £225,303 (2023: £0) which are secured on a fixed and floating charge over the assets concerned.
Director's confirmations
The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
|
SHALI MED LTD
REGISTERED NUMBER: 14008891
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2024
These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.
The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved and authorised for issue by the board and were signed on its behalf on 14 October 2024.
|